Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 106

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 106
---
    Non-vested
    RSUs
     
    RSUs

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31, 2024

    29,219

    $
    10.80

    Granted

    —

    —

    Vested

    (9,270
    ) 

    (11.82
    )

    Forfeited

    —

    —

    Non-vested at June 30, 2025

    19,949

    $
    10.67 

    20 

The
total number of RSUs granted during the three months ended June 30, 2025 and 2024 was 0 and 25,800
respectively. The total number of RSUs granted during the six months ended June 30, 2025 and 2024 was 0 and 25,800
respectively. 

The
Company recognized stock-based compensation expense related to RSU vesting amortization of $51,910 and $13,975 for the
three months ended June 30, 2025 and 2024, respectively, which is included in general and administrative expenses in the condensed
consolidated statements of operations. The Company recognized stock-based compensation expense related to RSU vesting amortization
of $103,820 and $13,975 for the six months ended June 30, 2025 and 2024, respectively, which is included in general
and administrative expenses in the condensed consolidated statements of operations.

NOTE
7 – SEGMENT DISCLOSURE

The
clinical-stage biotech segment focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus
is to selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain
receptor in human physiology. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way
to prevent the transmission of pain perception to the CNS. Our goal is to develop a novel and proprietary class of NaV blockers
that target the body’s peripheral nervous system. This segment is currently pre-revenue.

The
accounting policies of the clinical-stage biotech segment are the same as those described in the summary of significant accounting
policies.

The
chief operating decision maker assesses performance for the clinical-stage biotech